• 2019-07
  • 2019-08
  • 2019-09
  • 2019-10
  • 2019-11
  • 2020-03
  • 2020-07
  • 2020-08
  • 2021-03
  • g A cos m B sin m for some m


    g(θ ) = A cos(mθ ) + B sin(mθ ) for some m ∈ and ρ → f ( ρ ) must solve the Bessel equation Z √
    Summing up, we obtain
    a family indexed by m ∈ Z \ ±1 , p ∈ N . Apart from m = for which the eigenfunction is unique after normalisation, the eigenspace associated to λm,p is of dimension 2.
    Similar computations for the case of a cylinder of height h and radius a lead to the result λm, p,l = a

    lπ z
    If h is small compared to a, the contribution of the ( lhπ )2 term is too big and we will thus typically not see the eigenvalues such that l > in the z variable, an approximation precise up to O(( ha )2 ) errors. As a consequence, only the corresponding modes for l = will be observed, and we note that these are exactly the 2D modes.
    Under this smallness assumption, it is interesting to note that
    from the point of view of Turing instabilities, it is a good approxi-mation to neglect the z variable and focus on ⊂ R2 as a disk.
    Ferrand, N., Gnanapragasam, A., Dorothee, G., Redeuilh, G., et al., 2014. Loss of WISP2/CCN5 in estrogen-dependent MCF7 human breast cancer ABT-888 (Veliparib) promotes a stem-like cell phenotype. PloS One 9 (2).
    Haycock, J.W., 2011. 3D cell culture: a review of current approaches and techniques.
    Jurasz, P., Alonso-Escolano, D., Radomski, M.W., 2004. Platelet-cancer interactions: mechanisms and pharmacology of tumour cell induced platelet aggregation. Br. J. Pharmacol. 143, 819–826.
    Painter, K.J., 2009. Modelling cell migration strategies in the extracellular matrix. J.
    Painter, K.J., 2018. Mathematical models for chemotaxis and their applications in self-organisation phenomena. J. Theor. Biol.
    Schlüter, D.K., Ramis-Conde, I., Chaplain, M., 2012. Computational modeling of sin-gle-cell migration: the leading role ABT-888 (Veliparib) of extracellular matrix fibers. Biophys. J. 103
    Shi, M.M., Godleski, J.J., Paulauskis, J.D., 1995. Molecular cloning and post-tran-scriptional regulation of macrophage inflammatory protein-1α in alveolar macrophages. Biochem. Biophys. Res. Commun. 211 (1), 289–295.
    Zhao, Q., Barclay, M., Hilkens, J., Guo, X., et al., 2010. Research interaction between circulating galectin-3 and cancer-associated MUC1 enhances tumour cell homo-typic aggregation and prevents anoikis. Mol. Cancer 9.
    Contents lists available at ScienceDirect
    Journal of Inorganic Biochemistry
    journal homepage:
    A cisplatin-based platinum(IV) prodrug containing a glutathione s-transferase inhibitor to reverse cisplatin-resistance in non-small cell lung cancer 
    Hong Chen, Xinyi Wang, Shaohua Gou
    Pharmaceutical Research Center and School of Chemistry and Chemical Engineering, Jiangsu Province Hi-Tech Key Laboratory for Bio-medical Research, Southeast University, Nanjing 211189, China
    Pt(IV) prodrug
    Glutathione s-transferase
    Cisplatin resistance
    Non-small cell lung cancer 
    A Pt(IV) prodrug of cisplatin containing a glutathione s-transferase (GSTs) inhibitor 6-(7-nitro-2,1,3-benzox-adiazol-4-ylthio)hexanol (NBDHEX), complex 1, was designed and studied aiming to overcome cisplatin-re-sistance and reduce its toxicity by inhibiting GSTs overexpressed in cancer cells. The complex could be reduced to release its active Pt(II) species and axial ligand in the presence of ascorbic acid. In cytotoxicity study, complex 1 showed more potent anticancer activity than cisplatin and NBDHEX against all the tested cancer cells, espe-cially toward cisplatin resistant A549/DDP cells with a resistance factor value of 0.37. By effectively inhibiting GSTs, complex 1 was found to be able to promote higher platinum uptake and cause more severe DNA damage in both A549 cells and A549/DDP cells as compared with cisplatin. Further mechanism study indicated that it could trigger cell death via an apoptotic pathway. In vivo tests on A549 xenograft tumor mice model showed that complex 1 presented higher tumor inhibiting rate and lower toxicity than cisplatin as well. In all, the Pt(IV) prodrug has potential to be developed as an anticancer agent.